Product Pipeline

Neratinib across the breast cancer therapy spectrum

	Phase I	Phase II	Phase III	Registration	Approval
HER2+ Breast Cancer					US: 7/17 EC: 8/18
Extended adjuvant *Neratinib monotherapy*	CONTROL ExteNET (Phase III HER2+ EBC)			EAP/MAP	Australia: 3/19 Canada: 7/19 Argentina:8/19 Hong Kong: 9/19
Metastatic *Monotherapy or combo therapy*	FB-10: T-DM1 + neratinib NEfERTT (Phase II HER2+MBC) NALA (Phase III 3rd Line HER2+ MBC)			sNDA: 6/19	
Metastatic w/ brain mets *Monotherapy or combo therapy*	TBCRC-022				
HER2-mutant Breast Cancer/Solid Tumors					
Metastatic *Neratinib (± fulvestrant in MBC)*	SUMMIT- Breast HRC+ SUMMIT - Cervical SUMMIT (Basket Trial) Phase II Trial (WashU)				

Puma Biotechnology

Copyright 2019 Puma Biotechnology